Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: July 29, 2022 Report Code: GDGMDHC22254IDB-ST

Select Item

Ulcerative Colitis Pipeline Drugs Market Overview

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 20, 51, 51, 3, 100, 30 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 11 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

180 Life Sciences Corp
9 Meters Biopharma Inc
AbbVie Inc
Abivax SA
Accro Bioscience Suzhou Co Ltd
Aclaris Therapeutics Inc
Adiso Therapeutics Inc
Affilogic SAS
Akebia Therapeutics Inc
Akeso Inc
Algernon Pharmaceuticals Inc
Alpha Cancer Technologies Inc
AltruBio Inc
Alvotech ehf
Am-Pharma BV
Amgen Inc
Amide Technologies Inc
Applied Molecular Transport Inc
Aqilion AB
Aravive Inc
Artelo Biosciences Inc
Artizan Biosciences Inc
Asieris Pharmaceuticals Co Ltd
Asta Pharmaceuticals Co Ltd
AstraZeneca Plc
Atlantic Healthcare Plc
Avesthagen Ltd
Avexegen Therapeutics Inc
Azora Therapeutics Australia Pty Ltd
BenevolentAI Ltd
Bilix Co Ltd
Bio-Thera Solutions Ltd
Biocon Ltd
BioGaia AB
Biohaven Pharmaceutical Holding Company Ltd
Biora Therapeutics Inc
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Captor Therapeutics SA
Cellix Bio Pvt Ltd
Celltrion Inc
Chain Biotechnology Ltd
ChemoCentryx Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chong Kun Dang Holdings Corp
ChunLab Inc
Circle33 LLC
Claritas Pharmaceuticals Inc
ClostraBio Inc
Cloud Pharmaceuticals Inc
Comera Life Sciences Inc
Cosmo Pharmaceuticals NV
Cristcot HCA LLC
Cureveda LLC
Dadang & BIO Co Ltd
Denali Therapeutics Inc
DeNovX LLC
Devonian Health Group Inc
Direct Biologics LLC
DM Bio Ltd
DNX Biopharmaceuticals Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Eli Lilly and Co
enGene Inc
Ensign Pharmaceutical Inc
Exeliom Biosciences SAS
F. Hoffmann-La Roche Ltd
Ferring International Center SA
First Wave BioPharma Inc
Formycon AG
Fzata Inc
Galapagos NV
Galmed Pharmaceuticals Ltd
Genentech USA Inc
Genor BioPharma Co Ltd
Giiant Pharma Inc
Gossamer Bio Inc
GSK plc
Guangzhou Magpie Pharmaceutical Co Ltd
Gusto Global LLC
Han Wha Pharma Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hefei Cosource Pharmaceutical Inc
Hillhurst Biopharmaceuticals Inc
Himuka AM Pharma Corp
Holy Stone Healthcare Co Ltd
Hoth Therapeutics Inc
Huabo Biopharm (Shanghai) Co Ltd
Ichnos Sciences Inc
Iltoo Pharma
Immix BioPharma Inc
Immunic Inc
Impetis Biosciences Ltd
InDex Pharmaceuticals Holding AB
Innovation Pharmaceuticals Inc
Innovative Pharmacology Research
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
Intact Therapeutics
Intas Pharmaceuticals Ltd
Intract Pharma Ltd
Invea Therapeutics Inc
Istesso Ltd
Janux Therapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Kiniksa Pharmaceuticals Ltd
KoBioLabs Inc
Korea Pharma Co Ltd
Koutif Therapeutics LLC
Kyorin Pharmaceutical Co Ltd
Landos Biopharma Inc
LegoChem Biosciences Inc
LG Chem Ltd
LTT Bio-Pharma Co Ltd
Lumen Bioscience Inc
Lynk Pharmaceutical Hangzhou Co Ltd
MAKScientific LLC
Malachite Innovations Inc
Merck & Co Inc
Mesoblast Ltd
Metacrine Inc
Metagen Therapeutics Inc
Microba Life Sciences Ltd
Microbiotica Ltd
Mitsubishi Tanabe Pharma Corp
Morphic Therapeutic Inc
MRM Health NV
Nano Intelligent Biomedical Engineering Corp
NeuClone Pty Ltd
Nexbiome Therapeutics
Nexel Co Ltd
Novan Inc
Novartis AG
Novellus Therapeutics Ltd
Novome Biotechnologies Inc
Nubiyota LLC
Numedii Inc
Oncodesign SA
Oncostellae SL
Oryn Therapeutics
OSE Immunotherapeutics SA
Palatin Technologies Inc
Palo BioFarma SL
PanTheryx Inc
Paradigm Biopharmaceuticals Ltd
Parvus Therapeutics Inc
Pfizer Inc
Pharmabiome AG
Pharmapraxis
Pharmaxis Ltd
PNB Vesper Life Science Pvt Ltd
Praeventix LLC
Prometheus Biosciences Inc
Protab Ltd
Protagonist Therapeutics Inc
Protalix BioTherapeutics Inc
Puretech Health Plc
Qu Biologics Inc
Rebiotix Inc
Regentys Corp
Reistone Biopharma Co Ltd
RhemaStem SRLS
Rhizen Pharmaceuticals SA
Ribon Therapeutics Inc
Salix Pharmaceuticals Ltd
Samsung Bioepis Co Ltd
Sandoz International GmbH
Saniona AB
Santhera Pharmaceuticals Holding AG
Sareum Holdings Plc
Semorex Technologies Ltd
Senda Biosciences Inc
Seres Therapeutics Inc
Servatus Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Jiyu Pharmaceutical Technology Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shaperon Inc
Siam Bioscience Co Ltd
StemRIM Inc
sterna biologicals Gmbh & Co KG
Sublimity Therapeutics HoldCo Ltd
Suono Bio Inc
Surrozen Inc
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Huyun New Drug Research and Development Co Ltd
Synedgen Inc
Synlogic Inc
Takeda Pharmaceutical Co Ltd
Tarus Therapeutics Inc
TheraSource LLC
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tianjin Hemay Pharmaceutical Co Ltd
Tillotts Pharma AG
Torrent Pharmaceuticals Ltd
Vedanta Biosciences Inc
Ventyx Biosciences Inc
Vivreon Biosciences LLC
Voronoi Group
Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ulcerative Colitis – Overview

Ulcerative Colitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ulcerative Colitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ulcerative Colitis – Companies Involved in Therapeutics Development

Ulcerative Colitis – Drug Profiles

Ulcerative Colitis – Dormant Projects

Ulcerative Colitis – Discontinued Products

Ulcerative Colitis – Product Development Milestones

Featured News & Press Releases

Jul 27, 2022: EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults

Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)

Jul 18, 2022: Prometheus Biosciences completes enrollment of the ARTEMIS-UC cohort 1 phase 2 study in ulcerative colitis

Jul 07, 2022: Biora Therapeutics announces successful completion of second device performance study in human subjects for its targeted therapeutics platform

Jul 06, 2022: Applied Molecular Transport announces top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis

Jul 06, 2022: Applied Molecular Transport to report top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis

Jul 04, 2022: Innovent Phase II ulcerative colitis antibody trial doses first subject

Jun 20, 2022: EMA accepts Sandoz’s application for high concentration of biosimilar

Jun 08, 2022: Prometheus Biosciences provides enrollment update in APOLLO-CD and ARTEMIS-UC global phase 2 Studies

May 31, 2022: Biora Therapeutics shares presentation of patient data establishing correlation between drug levels in colon and patient outcomes in ulcerative colitis

May 27, 2022: The lancet publishes results from phase 3 induction and maintenance programs evaluating Upadacitinib (RINVOQ) in ulcerative colitis

May 24, 2022: InDex Pharmaceuticals to exhibit at Digestive Disease Week

May 24, 2022: Pfizer presents ELEVATE pivotal findings demonstrating etrasimod’s potentially best-in-class profile in ulcerative colitis

May 24, 2022: Fifty percent of patients with ulcerative colitis treated with Mirikizumab achieved clinical remission at one year in Lilly’s pivotal phase 3 study

May 24, 2022: Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate AVT04 and reference product Stelara

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Ulcerative Colitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ulcerative Colitis – Dormant Projects, 2022

Ulcerative Colitis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Gastrointestinal reports
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more